Table 5.
Method | N | Median (95% CI) OS, mo | HR (JULIET vs CORAL Follow up) | |||
---|---|---|---|---|---|---|
JULIET | CORAL follow-up | JULIET | CORAL follow-up | Estimate (95% CI) | P | |
OS | ||||||
Unadjusted analyses | 166 | 205 | 8.25 (5.82, 11.70) | 5.13 (3.88, 6.21) | 0.65 (0.51, 0.83) | <.001* |
Adjusted analyses† | ||||||
FSW | 163 | 205 | 8.25 (5.82, 12.42) | 4.86 (3.52, 6.08) | 0.60 (0.44, 0.77) | <.001* |
SMRW | 163 | 205 | 8.25 (5.82, 12.42) | 4.04 (3.25, 5.75) | 0.57 (0.44, 0.73) | <.001* |
Method | N | ORR, (%) | Response rate difference (JULIET Main Cohort vs CORAL Follow-up) | |||
---|---|---|---|---|---|---|
JULIET main cohort | CORAL follow-up | JULIET main cohort | CORAL follow-up | Estimate (95% CI) | P | |
ORR | ||||||
Unadjusted analyses | 146 | 205 | 37% | 30% | 0.07 (–0.03, 0.17) | .191 |
Adjusted analyses† | ||||||
FSW | 143 | 205 | 38% | 29% | 0.09 (–0.01, 0.20) | .097 |
SMRW | 143 | 205 | 38% | 27% | 0.11 (0.00, 0.22) | .043* |
P < .05.
Age at initial diagnosis, status of disease, time to 2L start after diagnosis, prior HCT, and number of relapses were included in the adjusted analysis.